Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
American Journal of Hematology|January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Alejandro Gru, Carl Quinion, et al.
Blood|March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsSumithira Vasu, Shun He, Carolyn Cheney, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
American Journal of Hematology|July 24, 2015
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsDeborah M Stephens, Amy S Ruppert, William G Weirda, et al.
Blood|September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsRosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Blood|June 15, 2016
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialJoseph C Alvarnas, Jennifer Le Rademacher, Yanli Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Blood|November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabFarrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
American Journal of Hematology|January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Alejandro Gru, Carl Quinion, et al.
Blood|March 26, 2016
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsSumithira Vasu, Shun He, Carolyn Cheney, et al.
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
American Journal of Hematology|July 24, 2015
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsDeborah M Stephens, Amy S Ruppert, William G Weirda, et al.
Blood|September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsRosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Blood|June 15, 2016
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialJoseph C Alvarnas, Jennifer Le Rademacher, Yanli Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Blood|November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabFarrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Pageof 14